Antitumor activities of synthetic and natural stilbenes through antiangiogenic action

Cancer Science

Volumn 99, Issue 10, 2008, Pages 2083-2096

  Kimura, Yoshiyuki ^a   Sumiyoshi, Maho ^a   Baba, Kimiye ^b  

^a EHIME UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 3,4',5 TRIMETHOXYSTILBENE; 2 HYDROXYSTILBENE; 2,3 DIHYDROXYSTILBENE; 2,3,4',5 TETRAACETOXYSTILBENE 2 O DEXTRO GLUCOSIDE ACETATE; 2,3,4',5 TETRAHYDROXYSTILBENE 2 O DEXTRO GLUCOSIDE; 3 HYDROXY 4',5 DIMETHOXYSTILBENE; 3 HYDROXYSTILBENE; 3,4 DIHYDROXYSTILBENE; 4 HYDROXY 3 METHOXYSTILBENE; 4 HYDROXYSTILBENE; 4,4' DIHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; CASSIGAROL A; GELATINASE B; PICEATANNOL; PICEATANNOL TETRAACETATE; PICEID; PICEID ACETATE; RESVERATROL; RESVERATROL TRIACETATE; RESVERATROL TRIMETHYLETHER; RHAPONTIN; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL SPECIFICITY; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VASCULARIZATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLONIC NEOPLASMS; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; ENZYME PRECURSORS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54949114722     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00948.x     Document Type: Article

References (60)

1. Kleiner DE, Steler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42-51.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
3. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
4. Macdougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Meta Rev 1995; 14: 351-62.
5. Di GH, Lu JS, Song CG, Li HC, Shen ZZ, Shao ZM. Over expression of aromatase protein in highly related to MMPs levels in human breast carcinomas. J Exp Clin Cancer Res 2005; 24: 601-67.
6. Kim SH, Cho NH, Kim K et al. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol 2006; 93: 330-7.
7. Zhao JX, Yang LP, Wang YF, Bai CX, Nan X, Shi SS, Pei XJ. Gelatinolytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in rat brain after implantation of 9L rat glioma cells. Eur J Neurol 2007; 14: 510-16.
8. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol 2000; 2: 737-44.
9. Kaliski A, Maggiorella L, Cengel KA et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005; 4: 1717-28.
10. Nagai S, Nakamura M, Yanai K et al. Glil contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Caner Sci 2008; 99: 1377-84.
11. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen recptor and invasion in prostate cancer. Cancer Res 2008; 68: 1128-35.
12. Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V, Munshi HG. Transforming growth factor-β1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res 2008; 6: 10-20.
13. Lee SO, Jeong YJ, Kim M, Kim CH, Lee IS. Suppresion of PMA-induced tumor cell invasion by capillarisin via the inhibition of NF-κB-dependent MMP-9 expression. Biochem Biophys Res Commun 2008; 366: 1019-24.
14. Kang JH, Han IH, Sung MK et al. Soybean saponin inhibits tumor cell metastasis by modulating expressions of MMP-2, MMP-9 and TIMP-2. Cancer Lett 2008; 261: 84-92.
15. Cortes-Reynosa P, Robledo T, Macias-Silva M, Wu SV, Salazar EP. Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells. Matrix Biol 2008; 27: 220-31.
16. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci 2008; 99: 553-63.
17. Yoshioka I, Tsuchiya Y, Aozuka Y et al. Urinary trypsin inhibitor suppresses surgical stress-facilitated lung metastasis of murine colon 26-L5 carcinoma cells. Anticancer Res 2005; 25: 815-20.
18. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix mettaloproteinase expression in metastatic tumor models. Nucl Med Biol 2006; 33: 227-37.
19. Ishizaki T, Katsumata K, Tsuchida A et al. Etodolac, a selective cyclooxygense-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med 2006; 17: 357-62.
20. Pan B, Zhao MH, Chen Z et al. Inhibitory effects of resistin-13-peptide on the proliferation, adhesion, and invasion of MDA-MB-231 in human breast carcinoma cells. Endocr Relat Cancer 2007; 14: 1063-71.
21. Park EY, Wilder ET, Lane MA. Retinol inhibits the invasion of retinoic acid-resistant colon cancer cell in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels. Nutr Cancer 2007; 57: 66-77.
22. Zhao T, Xia WH, Zheng MQ, Lu CQ, Han X, Sun YJ. Surgical excision promotes tumor growth and metastasis by promoting expression of MMP-9 and VEGF in a breast cancer model. Exp Oncol 2008; 30: 60-4.
23. Sigstedt SC, Hooten CJ, Callewaert MC et al. Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells. Int J Oncol 2008; 32: 1085-90.
24. Chang CK, Hung WC, Chang HC. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med 2008; Post print; 10.1111/ j.1582-4934.2008.00215x.
25. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
26. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of actin. Exp Cell Res 2006; 312: 594-607.
27. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Predatr Surg 2007; 42: 1-11.
28. Folkman J, Klagsbrum M. Angiogenic factors. Science 1987; 235: 442-7.
29. Klagrbrum M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-39.
30. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
31. Yi T, Yi Z, Cho SG et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008; 68: 1843-50.
32. Xiao D, Singh SV. Phenethyl isocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res 2007; 67: 2239-46.
33. Lin CM, Chang H, Chen YH, Li SY, Wu IH, Chiu JH. Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int Immunopharmacol 2006; 6: 1690-8.
34. Itokawa T, Nokihara H, Nishioka Y et al. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 2002; 1: 295-302.
35. Chen Y, Zhang Y-X, Li M-H et al. Antiangiogenic activity of 11, 11′-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola. Biochem Biophys Res Commun 2005; 329: 1334-42.
36. Kanno S, Oda N, Abe M et al. Role of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000; 19: 2138-46.
37. Bernatchez PN, Soker S, Sirois MG. Vascular endothelial growth effect on endothelia cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 1999; 274: 31047-54.
38. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996; 15: 4919-27.
39. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5: 3-10.
40. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
41. Meyer M, Clauss M, Lepple-Wienhues A et al. A novel vascular endothelia growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18: 363-74.
42. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receotors in the regulation of angiogenesis and lymphagiogenesis. Oncogene 2000; 19: 5598-605.
43. Kimura Y, Okuda H. Resveratrol isolated from Polygonum cuspidatum rooot prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 2001; 131: 1844-9.
44. Kimura Y, Kido T, Takaku T, Sumiyoshi M, Baba K. Isolation of anti-angiogenic substance from Agricuds blazei Murill: Its antitumor and antimetastatic actions. Cancer Sci 2004; 95: 758-64.
45. Kimura Y, Sumiyoshi M. Antitumor and antimetastatic actions of eicosapentaenoic acid ethylester and its by-products formed during accelerated stability testing. Cancer Sci 2005; 96: 441-50.
46. Kimura Y, Baba K. Antitumor and antimetastatic activities of Angelica keiskei roots, Part 1: Isolation of an active substance, xanthoangelol. Int J Cancer 2003; 106: 429-37.
47. Albuquerque MLC, Waters CM, Salvia U, Schnaper HW, Flozak A. Shear stress enhances human endothelial cell wound closure in vitro. Am J Physiol Heart Circ Physoiol 2000; 279: H293-302.
48. Kimura Y, Okuda T. Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice. J Pharm Pharmacol 2000; 52: 1287-95.
49. Kimura Y, Baba K, Okuda T. Inhibitory effects of active substances isolated from Cassia garretiana heartwood on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice (Part 1). Anticancer Res 2000; 20: 2899-906.
50. Kimura Y, Baba K, Okuda T. Inhibitory effects of active substances isolated from Cassia garretiana heartwood on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice (Part 2). Anticancer Res 2000; 20: 2923-30.
51. Okada Y, Gonoji Y, Naka K et al. Matrix metalloproteinase 9 (92-kDa gelatinase type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymatic properties. J Biol Chem 1992; 267: 21712-19.
52. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995; 270: 18506-11.
53. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell a-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bounds of the catalytic domain. J Biol Chem 1997; 272: 25628-6635.
54. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548-55.
55. Desrivières S, Lu H, Peyri N, Soria C, Legrand Y, Ménashi S. Activation of the 92 kDa type IV collagenase by tissue kallikrein. J Cell Physiol 1993; 157: 587-93.
56. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267: 4583-91.
57. O'connell JP, Willenbrock F, Docherty AJ, Eaton D, Murphy G. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor metalloproteinase interactions of gelatinase B. J Biol Chem 1994; 269: 14967-73.
58. von Bredow DC, Cress AE, Howard EW, Bowden GT, Nagle RB. Activation of gelatinase-tissue-inhibitor-of metalloproteinase complexes by matrilysin. Biochem J 1998; 331: 965-72.
59. Knäuper V, Smith B, Lóez-Otin C, Murphy G. Activation of progelatinase B (proMMP-9) by active collagenase-2 (MMP-13). Eur J Biochem 1997; 248: 369-73.
60. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-76.